Kinetics and organ distribution of allogeneic natural killer lymphocytes transfused into patients suffering from renal cell carcinoma

Stem Cells and Development

Volumn 13, Issue 3, 2004, Pages 307-314

  Brand, J M ^a   Meller, B ^a   Von Hof, K ^a   Luhm, J ^a   Bahre M ^a   Kirchner, H ^a   Frohn, Christoph ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CLEMASTINE FUMARATE; FLUOROURACIL; HLA DR ANTIGEN; INDIUM 111; INTERLEUKIN 2; RANITIDINE;

ADOPTIVE IMMUNOTHERAPY; ALLELE; ARTICLE; BLOOD; BLOOD DONOR; BONE MARROW; CANCER PATIENT; CELL CULTURE; CELL KINETICS; CELL SURVIVAL; CIRCULATION; CLINICAL ARTICLE; CLINICAL TRIAL; EXCRETION; HOST; HUMAN; HUMAN CELL; INJECTION; ISOTOPE LABELING; KIDNEY CARCINOMA; LIVER; LUNG; LYMPHOCYTE TRANSFUSION; METASTASIS; NATURAL KILLER CELL; ORGAN DISTRIBUTION; PATIENT MONITORING; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RADIOACTIVITY; SPLEEN; WHOLE BODY SCINTISCANNING;

CARCINOMA, RENAL CELL; GENES, MHC CLASS I; HLA-DR ANTIGENS; HUMANS; KILLER CELLS, NATURAL; LYMPHOCYTE SUBSETS; NEOPLASM METASTASIS; POLYMERASE CHAIN REACTION; TISSUE DISTRIBUTION; TRANSPLANTATION, HOMOLOGOUS;

EID: 2942560758     PISSN: 15473287     EISSN: None     Source Type: Journal    
DOI: 10.1089/154732804323099235     Document Type: Article

References (28)

1. Rosenberg SA, MT Lotze, LM Muul, S Leitman, AE Chang, SE Ettinghausen, YL Matory, JM Skibber, E Shiloni, JT Vetto et al. (1985). Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 313:1485-1492.
2. Hayakawa K, T Morita, LB Augustus, AC von Eschenbach and K Itoh. (1992). Human renal-cell carcinoma cells are able to activate natural killer cells. Int J Cancer 51:290-295.
3. Barao I and JL Ascensao. (1998). Human natural killer cells. Arch Immunol Ther Exp Warsz 46:213-229.
4. Peter HH, J Pavie-Fischer, WH Fridman, C Aubert, JP Cesarini, R Roubin and FM Kourilsky. (1975). Cell-mediate cytotoxicity in vitro of human lymphocytes against a tissue culture melanoma cell line (igr3). J Immunol 115:539-548.
5. Escudier B, F Farace, E Angevin, F Charpentier, G Nitenberg, F Triebel and T Hercend. (1994). Immunotherapy with interleukin-2 (IL2) and lymphokine-activated natural killer cells: improvement of clinical responses in metastatic renal cell carcinoma patients previously treated with IL2. Eur J Cancer 30A: 1078-1083.
6. Frohn C, C Doehn, C Durek, A Böhle, P Schlenke, D Jocham and H Kirchner. (2000). Feasibility of the adoptive transfusion of allogenic HLA-matched NK-cells in patients with renal cell carcinoma. J Immunother 23:499-504.
7. Klingemann HG. (2001). Cellular therapy of cancer with natural killer cells: will it ever work? J Hematother Stem Cell Res 10:23-26.
8. Chiorean EG and JS Miller. (2001). The biology of natural killer cells and implications for therapy of human disease. J Hematother Stem Cell Res 10:451-463.
9. Zeis M, L Uharek, B Glass, T Gaska, J Steinmann, W Gassmann, H Löffler and RW Muller. (1995). Allogeneic NK cells as potent antileukemic effector cells after allogeneic bone marrow transplantation in mice. Transplantation 59:1734-1736.
10. Luhm J, JM Brand, P Koritke, M Höppner, H Kirchner and C Frohn. (2002). Large-scale generation of natural killer lymphocytes for clinical application. J Hematother Stem Cell Res 11:651-657.
11. Tourani JM, C Pfister, JF Berdah, A Benhammouda, P Salze, A Monnier, B Paule, P Guillet, Y Chretien, Y Brewer, M Di Palma, M Untereiner, E Malaurie, Z Tadrist, JM Pavlovitch, D Hauteville, A Mejean, M Azagury, D Mayeur, V Lucas, I Krakowski, D Larregain-Fournier, H Abourachid, JM Andrieu and C Chastang. (1998). Outpatient treatment with subcutaneous interleukin-2 and interferon-α administration in combination with fluorouracil in patients with metastatic renal cell carcinoma: results of a sequential nonrandomized phase II study. Subcutaneous Administration Proleukin Program Cooperative Group. J Clin Oncol 16:2505-2513.
12. Council of Europe. (2000). Guide to the preparation, use and quality assurance of blood components. Council of Europe Press, Strasbourg.
13. Lanier LL. (1997). Natural killer cells: from no receptors to too many. Immunity 6:371-378.
14. Frohn C, P Schlenke, B Ebel, C Dannenberg, G Bein and H Kirchner. (1998). DNA typing for natural killer cell inhibiting HLA-Cw groups NK1 and NK2 by PCR-SSP. J Immunol Methods 218:155-160.
15. Bein G, R Gläser and H. Kirchner (1992). Rapid HLA-DRB1 genotyping by nested PCR amplification. Tissue Antigens 39:68-73.
16. Ranek L. (1976). Cytophotometric studies of the DNA, nucleic acid and protein content of liver cell nuclei from patients with virus hepatitis. Acta Pathol Microbiol Scand 84:1-8.
17. Kruskall MS, TH Lee, SF Assmann, M Laycock, LA Kalish, MM Lederman and MP Busch. (2001). Survival of transfused donor white blood cells in HIV-infected recipients. Blood 98:272-279.
18. Lee TH, T Paglieroni, H Ohto, PV Holland and MP Busch. (1999). Survival of donor leukocyte subpopulations in immunocompetent transfusion recipients: frequent long-term microchimerism in severe trauma patients. Blood 93:3127-3139.
19. Lee TH, E Donegan, S Slichter and MP Busch. (1995). Transient increase in circulating donor leukcotyes after allogeneic transfusions in immunocompetent recipients compatible with donor cell proliferation. Blood 85:1207-1214.
20. Adams PT, RD Davenport, DA Reardon and MS Roth. (1992). Detection of circulating donor white blood cells in patients receiving multiple transfusions. Blood 80:551-555.
21. Whiteside TL, NL Vujanovic and R Herberman. (1998). Natural killer cells and tumor therapy. In: Specificity, Function and Development of NK Cells. K. Kärre and M. Colonna, eds.) Springer, Heidelberg, pp. 221-244.
22. Reed WF, TL Lee, E Trachtenberg, M Vinson and MP Busch. (2001). Detection of microchimerism by PCR is a function of amplification strategy. Transfusion 41:39-44.
23. Read EJ, AM Keenan, CS Carter, PS Yolles, and RJ Davey. (1990). In vivo traffic of indium-III-oxine labeled human lymphocytes collected by automated apheresis. J Nucl Med 31:999-1006.
24. Lavender JP, JM Goldman, RN Arnot and ML Thakur. (1977). Kinetics of indium-III labeled lymphocytes in normal subjects and patients with Hodgkin's disease. Br Med J 2:797-799.
25. Gainey MA, JA Siegel, EM Smergel and BJ Jara. (1988). Indium-III-labeled white blood cells: dosimetry in children. J Nucl Med 29:689-694.
26. Hamilton D, RA Cowan, HL Sharma, M Drayson, PM Nuttall, J Wagstaff, DP Deakin and D Crowther. (1988). The behavior of autologous indium-114m-labeled lymphocytes in patients with lymphoid cell malignancy. J Nucl Med 29:485-493.
27. Lotze MT, BR Line, DJ Mathisen and SA Rosenberg. (1980). The in vivo distribution of autologous human and murine lymphoid cells grown in T cell growth factor (TCGF): implications for the adoptive immunotherapy of tumors. J Immunol 125:1487-1493.
28. Hercend T, F Farace, D Baume, F Charpentier, JP Droz, F Triebel and B Escudier. (1990). Immunotherapy with lymphokine-activated natural killer cells and recombinant interleukin-2: a feasibility trial in metastatic renal cell carcinoma. J Biol Response Mod 9:546-555.